Cargando…
MON-LB119 Euglycemic Diabetic Ketoacidosis in a Patient on Canagliflozin Presenting With Hypoglycemia
Background: Sodium glucose co-transporter 2 (SGLT-2) inhibitors are newer class of antihyperglycemics that cause reversible inhibition of the sodium-glucose cotransporters in the renal proximal tubules resulting in increased urinary glucose. Common side effects include yeast and urinary tract infect...
Autores principales: | Inkollu, Sindhura, Korem, Sindhuja, Ganne, Sudha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209517/ http://dx.doi.org/10.1210/jendso/bvaa046.2155 |
Ejemplares similares
-
A Case of Euglycemic Diabetic Ketoacidosis Following Canagliflozin Therapy
por: Tuna, Kubra M, et al.
Publicado: (2021) -
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019) -
SUN-183 Prolonged Glycosuria after Canagliflozin Discontinuation in a Patient with Euglycemic Diabetic Ketoacidosis
por: Dai, Yufei, et al.
Publicado: (2019) -
SAT-LB118 Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Arao, Kevin A, et al.
Publicado: (2020) -
MON-LB124 Euglycemic Diabetic Ketoacidosis on Initiation of Ertugliflozin in a Patient With Type 2 Diabetes Mellitus Precipitated by a Ketogenic Diet
por: Richstein, Ryan, et al.
Publicado: (2020)